Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Japanese Nuclear Crisis Triggers Panic Buying Of Food And Drugs In China, Along With Selling Of Chinese Life Science Stocks

This article was originally published in PharmAsia News

Executive Summary

BEIJING - Virtual aftershocks from the 9.0 magnitude earthquake that rocked Japan, followed by a tsunami and a nuclear power plant crisis, are still reverberating across China

You may also be interested in...



Korea Begins To Assess Public Health, Industry Fallout From Japan Disaster

SEOUL - While a growing number of countries such as the U.S., Italy, France, Australia, New Zealand, Britain, China, India and Kyrgyzstan are urging their nationals in Japan to evacuate, South Korea on Thursday started checking radiation levels of people coming into the country from Japan

Southwest Japan-heavy Takeda And Dainippon Sumitomo Spared Earthquake Damage, Others May Rebound, But Tokyo Headquarters' Quieted By Rail Disruptions

TOKYO - Offices across Tokyo remained closed Tuesday, stalling the operations of headquarters for many pharma and medical device companies in Japan as the city faced train and highway closures and threats of blackouts through the rest of the week. Meanwhile, stocks for many of the Japanese pharma tumbled on the Nikkei March 14 in response to the emergency at power plants in Fukushima prefecture

Fresh Off BMS Deal, Leading Chinese CRO WuXi PharmaTech Outlines Plan To Expand Biologics Business To Keep Pace With Big Pharma

BEIJING - Betting on the belief that Big Pharma will speed up the transfer of research and manufacturing to China, leading contract research organization WuXi PharmaTech is expanding its chemistry services even while preparing to launch a new biologics testing and production center near its headquarters in Shanghai

Related Content

UsernamePublicRestriction

Register

SC077434

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel